News Sentiment

CLYM sentiment intelligence

Climb Bio Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 42 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 14.00 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 34

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+8.5% over one week, +22.4% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

FMR LLC's Strategic Acquisition of Climb Bio Inc Shares

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction 8.5% Price confirming higher
Trend fit Trend active 22.4% over four weeks
Fair value 234.0% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 10
Neutral 31
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 34
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
GlobeNewswire 7
simplywall.st 4
MT Newswires 3
Stock Titan 3
Investing.com UK 2
Investing.com 2
GuruFocus 1

Event Lens

What the news is about

Classified themes
Market update 23
Earnings 10
Analyst action 4
Deals and strategy 3
Regulatory and legal 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-42 of 42
Simply Wall Street Direct company coverage

Climb Bio, Inc. (CLYM) Leadership & Management Team Analysis

This article provides an analysis of Climb Bio, Inc.'s (CLYM) leadership and management team. It details compensation for CEO Aoife Brennan, management and board tenure, and lists recent company updates including executive changes, regulatory designations, and financial activitie

Tone
Neutral 50/100
Event
Regulatory and legal
Published
13 Apr 2026 12:40
Source
Simply Wall Street
Bitget Direct company coverage

ELYM Stock: Transition from Eliem Therapeutics to Climb Bio

Eliem Therapeutics, formerly known as ELYM, has rebranded to Climb Bio (CLYM) and shifted its strategic focus from neurology to autoimmune disease treatments. This transformation followed the acquisition of Tenet Medicines in mid-2024, which brought budoprutug, a promising therap

Tone
Positive 71/100
Event
Deals and strategy
Published
12 Feb 2026 12:10
Source
Bitget
Market source Direct company coverage

Eliem Therapeutics Changes Name to Climb Bio

Eliem Therapeutics, Inc. has officially changed its corporate name to Climb Bio, Inc. and will trade under the new Nasdaq ticker symbol "CLYM" starting October 3rd. This rebranding signifies the company's refocused mission on developing treatments for immune-mediated diseases, wi

Tone
Positive 66/100
Event
Market update
Published
02 Oct 2024 23:04
Source
Market source
GlobeNewswire Direct company coverage

Eliem Therapeutics Announces Rebranding and Corporate Name Change to Climb Bio, Inc.

Eliem Therapeutics, Inc. has announced its rebranding to Climb Bio, Inc., effective October 3, 2024, trading under the new Nasdaq symbol "CLYM." This change reflects the company's refocused mission to develop treatments for immune-mediated diseases, following its acquisition of T

Tone
Positive 72/100
Event
Deals and strategy
Published
02 Oct 2024 09:00
Source
GlobeNewswire